Male patients with prolactinomas exhibit greater invasiveness, resistance to dopamine agonists, making treatment more challenging. This study aims to explore the potential different genes contributing to sex disparities in prolactinomas.
Materials and Methods:
Weighted gene co-expression network analysis and differential expressed genes analysis were performed to identify sex-related hub genes. In addition, bioinformatics analyses were conducted to understand gene localization on chromosomes, gene regulatory networks, signaling pathways, and their relationship with immune function, which was verified in 21 human prolactinoma samples.
Results:
A total of 21 sex-related hub genes were identified. The hub genes in males included nine Y chromosome genes and six autosomal genes, while females had six specific genes. Further predictions using the NetworkAnalyst online tool suggested that transcription factors (REST, androgen receptor) and microRNAs (miR-27a-3p, miR-146a-5p) may be involved in regulating the above sex-related hub genes. CIBERSORT analysis revealed that prolactinomas in males showed significant infiltration of resting dendritic cells and naive CD4+ T cells. Correlation analysis between sex-related hub genes and immune checkpoint genes indicated that male hub genes were positively correlated with CD47 and CEACAM1, while showing a strong negative correlation with CD28, TNFSF14, and CD226. Finally, similar changes of gene expression in our surgical prolactinoma samples were confirmed by RT-qPCR.
Conclusions:
In prolactinomas, the male hub genes and female hub genes are identified by our bioinformatics analysis. Our findings suggest that KDM5D, PDCD1, ELOA3BP, XRRA1, and SIGLEC12 serve as potential biomarkers for male prolactinomas, while SOX3, DMGDH, and NPAS1 may serve as potential biomarkers for female prolactinoma, providing a theoretical basis for targeted therapy.
Get full access to this article
View all access options for this article.
References
1.
AndereggenL, FreyJ, AndresRH, et al.Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. Sci Rep, 2021; 11(1):5122.
2.
AsaSL, MeteO, PerryA, OsamuraRY. Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol, 2022; 33(1):6–26.
3.
AshburnerM, BallCA, BlakeJA, et al.Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nature Genetics, 2000; 25(1):25–29.
4.
AuriemmaRS, PirchioR, PivonelloC, et al.Approach to the patient with prolactinoma. J Clin Endocrinol Metab, 2023; 108(9):2400–2423.
5.
BancaroN, CALìB, TroianiM, et al.Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer Cell, 2023; 41(3):602–619.e11.
6.
BindeaG, MlecnikB, HacklH, et al.ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics, 2009; 25(8):1091–1093.
7.
BustinSA, BenesV, GarsonJA, et al.The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem, 2009; 55(4):611–622.
8.
ChansonP, MaiterD. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metabolism, 2019; 33:101290.
9.
ChenH, BoutrosPC. VennDiagram: A package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics, 2011; 12:35.
10.
ChenJ, BardesEE, AronowBJ, JeggaAG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res, 2009; 37(Web Server issue):W305–W311.
11.
ConesaA, MadrigalP, TarazonaS, et al.A survey of best practices for RNA-seq data analysis. Genome Biol, 2016; 17:13.
12.
CozziR, AmbrosioMR, AttanasioR, et al.Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: Prolactin-secreting tumors. Eur J Endocrinol, 2022; 186(3):P1–P33.
13.
CrespoJ, WuK, LiW, et al.Human naive T cells express functional CXCL8 and promote tumorigenesis. J Immunol, 2018; 201(2):814–820.
14.
DelgrangeE, SassolasG, PerrinG, et al.Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien), 2005; 147(7):751.
15.
DelgrangeE, TrouillasJ, MaiterD, et al.Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. J Clin Endocrinol Metab, 1997; 82:2102–2107.
16.
DurinckS, SpellmanPT, BirneyE, HuberW. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc, 2009; 4(8):1184–1191.
17.
Duskin-BitanH, ShimonI. Prolactinomas in males: Any differences? Pituitary, 2020; 23(1):52–57.
18.
GelB, SerraE. karyoploteR: An R/Bioconductor package to plot customizable genomes displaying arbitrary data. Bioinformatics, 2017; 33(19):3088–3090.
19.
GelB, DíEZ-VillanuevaA, SerraE, et al.regioneR: An R/Bioconductor package for the association analysis of genomic regions based on permutation tests. Bioinformatics, 2016; 32(2):289–291.
20.
GinestetC. ggplot2: Elegant graphics for data analysis. J R Stat Soc Ser a Stat Soc, 2011; 174(1):245–246.
21.
GodfreyAK, NaqviS, CHMáTALL, et al.Quantitative analysis of Y-Chromosome gene expression across 36 human tissues. Genome Res, 2020; 30(6):860–873.
22.
HannenR, SteffaniM, VoellgerB, et al.Effects of anti-estrogens on cell invasion and survival in pituitary adenoma cells: A systematic study. J Steroid Biochem Mol Biol, 2019; 187:88–96.
23.
HauptS, CaramiaF, KleinSL, et al.Sex disparities matter in cancer development and therapy. Nat Rev Cancer, 2021; 21(6):393–407.
24.
HayatSMG, BianconiV, PirroM, et al.CD47: Role in the immune system and application to cancer therapy. Cell Oncol, 2020; 43(1):19–30.
HongQ, LiC, YingR, et al.Loss-of-function of sox3 causes follicle development retardation and reduces fecundity in zebrafish. Protein Cell, 2019; 10(5):347–364.
27.
HuB, MaoZ, JiangX, et al.Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma. Brain Res, 2018; 1698:204–212.
28.
HuF-F, LiuC-J, LiuL-L, et al.Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Brief Bioinform, 2021; 22(3):bbaa176.
29.
HuangY-H, ZhuC, KondoY, et al.CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature, 2015; 517(7534):386–390.
30.
Iglesias-EscuderoM, Arias-GonzálezN, Martínez-CáceresE. Regulatory cells and the effect of cancer immunotherapy. Mol Cancer, 2023; 22(1):26.
31.
JaquetP, OuafikL, SaveanuA, et al.Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab, 1999; 84:3268–3276.
32.
KidoT, LauY-FC. Roles of the Y chromosome genes in human cancers. Asian J Androl, 2015; 17(3):373–380.
33.
LangfelderP, HorvathS. WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics, 2008; 9:559.
34.
LangfelderP, HorvathS. Fast R functions for robust correlations and hierarchical clustering. J Stat Soft, 2012; 46(11).
35.
LasolleH, IlieMD, RaverotG. Aggressive prolactinomas: How to manage? Pituitary, 2020; 23(1):70–77.
36.
LiJ, LanZ, LiaoW, et al.Histone demethylase KDM5D upregulation drives sex differences in colon cancer. Nature, 2023; 619(7970):632–639.
37.
LiuG, HouG, LiL, et al.Potential diagnostic and prognostic marker dimethylglycine dehydrogenase (DMGDH) suppresses hepatocellular carcinoma metastasis in vitro and in vivo. Oncotarget, 2016; 7(22):32607–32616.
38.
Lopes-RamosCM, QuackenbushJ, DemeoDL. Genome-wide sex and gender differences in cancer. Front Oncol, 2020; 10:597788.
39.
LuoM, TangR, WangH. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset. J Neurooncol, 2023; 163(3):663–674.
40.
LyuL, JiangY, MaW, et al.Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling. Br J Cancer, 2023; 128(6):1117–1133.
41.
Marjanovic VicenticJ, DrakulicD, GarciaI, et al.SOX3 can promote the malignant behavior of glioblastoma cells. Cell Oncol (Dordr), 2019; 42(1):41–54.
42.
MeiY, BiWL, AgoliaJ, et al.Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary, 2021; 24(3):359–373.
43.
MesakFM, OsadaN, HashimotoK, et al.Molecular cloning, genomic characterization and over-expression of a novel gene, XRRA1, identified from human colorectal cancer cell HCT116Clone2_XRR and macaque testis. BMC Genomics, 2003; 4(1):32.
44.
MeteO, LopesMB. Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol, 2017; 28(3):228–243.
45.
MolitchME. Diagnosis and treatment of pituitary adenomas: A review. JAMA, 2017; 317(5):516–524.
46.
MoreS, BonnereauJ, WoutersD, et al.Secreted Apoe rewires melanoma cell state vulnerability to ferroptosis. Sci Adv, 2024; 10(42):eadp6164.
47.
NewmanAM, LiuCL, GreenMR, et al.Robust enumeration of cell subsets from tissue expression profiles. Nat Methods, 2015; 12(5):453–457.
48.
PalamarchukA, TsybaL, TomaselloL, et al.PDCD1 (PD-1) is a direct target of miR-15a-5p and miR-16-5p. Signal Transduct Target Ther, 2022; 7(1):12.
49.
PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012; 12(4):252–264.
50.
PengY, YinH, PeiX, et al.Cholesterol-activated stress granules reduce the membrane localization of DRD2 and promote prolactinoma dopamine agonists resistance. Acta Neuropathol Commun, 2025; 13(1):84.
RecouvreuxMV, FaraoniEY, CamillettiMA, et al.Sex differences in the pituitary TGFβ1 system: The role of TGFβ1 in prolactinoma development. Front Neuroendocrinol, 2018; 50:118–122.
53.
RitchieME, PhipsonB, WuD, et al.limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015; 43(7):e47.
54.
ShannonP, MarkielA, OzierO, et al.Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13(11):2498–2504.
55.
ShenX, HuK, ChengG, et al.KDM5D inhibit epithelial-mesenchymal transition of gastric cancer through demethylation in the promoter of Cul4A in male. J Cell Biochem, 2019; 120(8):12247–12258.
56.
SuS, LiaoJ, LiuJ, et al.Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res, 2017; 27(4):461–482.
57.
TehCHL, LohCC, LamKKY, et al.Neuronal PAS domain protein 1 regulates tyrosine hydroxylase level in dopaminergic neurons. J Neurosci Res, 2007; 85(8):1762–1773.
58.
ToulisKA, RobbinsT, ReddyN, et al.Males with prolactinoma are at increased risk of incident cardiovascular disease. Clin Endocrinol (Oxf), 2018; 88(1):71–76.
59.
TricaricoR, NicolasE, HallMJ, GolemisEA. X- and Y-linked chromatin-modifying genes as regulators of sex-specific cancer incidence and prognosis. Clin Cancer Res, 2020; 26(21):5567–5578.
60.
WangP-F, WangT-J, YangY-K, et al.The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy. J Neurooncol, 2018; 139(1):89–95.
61.
WangW, GuoM, XiaX, et al.XRRA1 targets ATM/CHK1/2-mediated DNA repair in colorectal cancer. Biomed Res Int, 2017; 2017:5718968.
62.
WierinckxA, DelgrangeE, BertolinoP, et al.Sex-related differences in lactotroph tumor aggressiveness are associated with a specific gene-expression signature and genome instability. Front Endocrinol (Lausanne), 2018; 9:706.
63.
YuG, WangL-G, HanY, HeQ-Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS, 2012; 16(5):284–287.
64.
ZhangF, ZhangQ, ZhuJ, et al.Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors. Cell Res, 2022; 32(12):1047–1067.
65.
ZhangZ, BartschJW, BenzelJ, et al.Selective estrogen receptor modulators decrease invasiveness in pituitary adenoma cell lines AtT-20 and TtT/GF by affecting expression of MMP-14 and ADAM12. FEBS Open Bio, 2020; 10(11):2489–2498.
66.
ZhouG, SoufanO, EwaldJ, et al.NetworkAnalyst 3.0: A visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res, 2019; 47(W1):W234–W241.
67.
ZhouQ, ZhouL-Q, LiS-H, et al.Identification of subtype-specific genes signature by WGCNA for prognostic prediction in diffuse type gastric cancer. Aging (Albany NY), 2020; 12(17):17418–17435.
